Key answer: Ozempic is not FDA-approved for weight loss
Ozempic (semaglutide) is FDA-approved as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes and to reduce the risk of major adverse cardiovascular events in certain adults with type 2 diabetes and established cardiovascular disease. It is not approved for chronic weight management or obesity treatment in people without diabetes. For weight loss, the FDA has approved other formulations and doses of semaglutide (e.g., Wegovy) and different medications explicitly labeled for chronic weight management.
What Ozempic is FDA-approved for
Type 2 diabetes management and cardiovascular risk reduction
Ozempic is a once-weekly injectable prescription medicine containing semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist. The FDA approved it to:
- Improve glycemic control as an adjunct to diet and exercise in adults with type 2 diabetes.
- Reduce the risk of major adverse cardiovascular events, such as stroke, myocardial infarction, and cardiovascular death, in adults with type 2 diabetes and established cardiovascular disease.
These approvals are supported by cardiovascular outcome trials that demonstrated a reduction in the risk of serious heart problems in people with type 2 diabetes and pre-existing heart disease when Ozempic was added to standard care.
What is FDA-approved for weight loss
Chronic weight management and obesity treatment
The FDA oversees distinct product approvals for chronic weight management. Medications with explicit weight-loss indications include orlistat, liraglutide (Saxenda) at a 3 mg dose, naltrexone-bupropion (Contrave), phentermine-topiramate (Qsymia), and semaglutide 2.4 mg (Wegovy). These products are studied and labeled for use in conjunction with a reduced-calorie diet and increased physical activity in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity. Some older products are also approved for short-term use in low-calorie diets for weight reduction in people with obesity. GLP-1 agonists approved specifically for weight management at higher doses than those used in diabetes are explicitly indicated for chronic weight control.
| Product (active ingredient) | FDA indication | Dose relevant for weight loss | Source type |
|---|---|---|---|
| Semaglutide (Wegovy) | Chronic weight management | 2.4 mg once weekly | FDA-approved prescribing information |
| Liraglutide (Saxenda) | Weight management | 3 mg once daily | FDA-approved prescribing information |
| Orlistat (Xenical, Alli) | Weight loss | 120 mg with meals | FDA-approved prescribing information |
| Naltrexone-bupropion (Contrave) | Weight management | Combination tablet | FDA-approved prescribing information |
| Phentermine-topiramate (Qsymia) | Weight management | Once daily | FDA-approved prescribing information |
Why the distinction matters
Using a medication outside its FDA-approved indication can affect dosing, monitoring, insurance coverage, and expectations for outcomes. Prescribing a drug for an unapproved indication is legal in some contexts (sometimes called off-label use), but patients should understand that the safety and effectiveness for that specific use may not have been reviewed by the FDA. For weight loss, clinicians may prescribe Ozempic off-label, and some people do lose weight; however, this use is not the same as a product evaluated and labeled by the FDA specifically for weight management. Off-label use may also involve different dosing considerations and monitoring needs.
Ozempic vs. Wegovy for weight loss
Same active ingredient, different doses and indications
Ozempic and Wegovy both contain semaglutide, but they are approved for different purposes and at different doses. Ozempic is indicated for diabetes and cardiovascular risk reduction, while Wegovy is indicated for chronic weight management at a 2.4 mg weekly dose. Wegovy’s approval for weight loss was supported by large trials in adults with obesity or overweight with related conditions, showing significant weight loss when combined with lifestyle changes. Using the correct product and dose for the intended outcome helps ensure that the benefits and risks have been formally evaluated and labeled by regulators.
Practical considerations if you’re considering semaglutide for weight loss
Consult your clinician and check coverage
If you are interested in medication-assisted weight loss, ask your clinician whether an FDA-approved option such as Wegovy or another indicated treatment is appropriate for your health status. Discuss potential benefits, side effects, monitoring needs, and costs, including insurance coverage. If a clinician prescribes Ozempic for weight loss, ask about the intended approach, dosing, and what to expect in terms of evaluation and follow-up. Lifestyle changes remain an important part of any weight-management plan, whether or not medication is used.
Summary
Ozempic is FDA-approved for type 2 diabetes and cardiovascular risk reduction, but not for weight loss. For weight management, the FDA has approved other products and doses of semaglutide (e.g., Wegovy), as well as other medications specifically labeled for chronic weight control. Understanding the specific indication and formulation helps ensure that use is safe, effective, and covered appropriately. Always discuss weight-loss options with a healthcare professional to tailor treatment to your health needs and goals.